Ask AI

Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

In this online program based on a symposium from EHA 2025, experts discuss emerging uses of CELMoDs for treating patients with relapsed/refractory multiple myeloma. Download slides, view an on-demand webcast, and read an expert commentary for more information on this topic.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb